Editing Psilocybin (section)

====Advocacy for tolerance====
Despite being illegal to possess without authorization in many Western countries, such as the UK, Australia, and some U.S. states, less conservative governments nurture the legal possession and supply of psilocybin and other psychedelic drugs. In [[Amsterdam]], authorities provide education on and promote the safe use of psychedelic drugs, such as psilocybin, to reduce public harm.<ref>{{Cite journal |vauthors=Hardon A, van Schipstal I, Berning M, Mishra S, Murray H, Mandler T, Kamps D, Hymans TD |date=December 2020 |title=Caring for "Hassle-Free Highs" in Amsterdam. |journal=Anthropology and Humanism |volume=45 |issue=2 |pages=212–22 |doi=10.1111/anhu.12298 |s2cid=228997721|doi-access=free |hdl=11245.1/a323041d-6737-4b4a-968e-9285d8d68ffa |hdl-access=free }}</ref> Similarly, religious groups like America's Uniao do Vegetal (UDV)<ref name="Pollan_2018">{{Cite book |title=Como mudar sua mente | vauthors = Pollan M |author1-link=Michael Pollan|date=2018 |publisher=Editora Intrinseca |isbn=9788551004173 |language=Portuguese |trans-title=How to kill your mind}}</ref> use psychedelics in traditional ceremonies.<ref>{{Cite book |title=Psychedelic mysticism: Transforming consciousness, religious experiences, and voluntary peasants in postwar America. |vauthors=Shipley M |date=November 2015 |publisher=Lexington Books |isbn=978-1-4985-0910-7}}</ref> A report from the U.S. Government Accountability Office (GAO) notes that people may petition the DEA for exemptions to use psilocybin for religious purposes.<ref>{{Cite web | vauthors = Adlin B |date=2024-07-15 |title=DEA's Process for Religious Use of Psychedelics Needs More Consistent Standards, Government Watchdog Agency Says |url=https://doubleblindmag.com/deas-process-for-religious-use-of-psychedelics-needs-more-consistent-standards-government-watchdog-agency-says/ |access-date=2024-07-17 |website=DoubleBlind Mag |language=en-US}}</ref>

From 1 July 2023, the Australian medicines regulator has permitted psychiatrists to prescribe psilocybin for the therapeutic treatment of treatment-resistant depression.<ref>{{Cite news | vauthors = Lu D |date=2023-06-30 |title=Australian psychiatrists can now prescribe MDMA and psilocybin: who can access them and how do they work? |language=en-GB |work=The Guardian |url=https://www.theguardian.com/australia-news/2023/jul/01/australian-psychiatrists-can-now-prescribe-mdma-and-psilocybin-who-can-access-them-and-how-do-they-work |access-date=2023-07-18 |issn=0261-3077}}</ref>

Advocates of legalization argue there is a lack of evidence of harm,<ref>{{Cite report |url=https://parliament.wa.gov.au/Parliament/commit.nsf/luInquiryPublicSubmissions/5F7C3C56F7ABD360482583A70009A934/$file/id.alt.063.190118.sub.Australian%20Psychedelic%20Society.pdf |title=Submission to the Western Australian Inquiry Into Alternative Approaches to Reducing Illicit Drug Use and Its Effects on the Community |date=30 January 2019 |publisher=Australian Psychedelic Society Inc. |access-date=August 23, 2021 |archive-url=https://web.archive.org/web/20210823040413/https://parliament.wa.gov.au/Parliament/commit.nsf/luInquiryPublicSubmissions/5F7C3C56F7ABD360482583A70009A934/$file/id.alt.063.190118.sub.Australian%20Psychedelic%20Society.pdf |archive-date=August 23, 2021 |url-status=live}}</ref><ref name="Johansen_2015">{{cite journal | vauthors = Johansen PØ, Krebs TS | title = Psychedelics not linked to mental health problems or suicidal behavior: a population study | journal = Journal of Psychopharmacology | volume = 29 | issue = 3 | pages = 270–279 | date = March 2015 | pmid = 25744618 | doi = 10.1177/0269881114568039 | s2cid = 2025731 }}</ref> and potential use in treating certain mental health conditions. Research is difficult to conduct because of the legal status of psychoactive substances.<ref name="Johnson_2018">{{cite journal | vauthors = Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE | title = The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | journal = Neuropharmacology | volume = 142 | pages = 143–166 | date = November 2018 | pmid = 29753748 | pmc = 6791528 | doi = 10.1016/j.neuropharm.2018.05.012 }}</ref> Advocates of legalization also promote the utility of "[[ego dissolution]]"<ref name="Pollan_2018" /> and argue bans are cultural discrimination against traditional users.<ref>{{Cite journal |vauthors=Rodd R |date=September 2018 |title=It's all you! Australian ayahuasca drinking, spiritual development, and immunitary individualism. |journal=Critique of Anthropology |volume=38 |issue=3 |pages=325–45 |doi=10.1177/0308275X18775818 |s2cid=149858755}}</ref>

In 2024, after calls for regulatory and legal change to expand terminally ill populations' access to controlled substances, two legal cases related to expanded access began moving through the federal courts under [[right-to-try law]]. The Advanced Integrative Medicine Science (AIMS) Institute in concert with the NPA filed a series of lawsuits seeking both the rescheduling of and expanded right-to-try access to psilocybin.<ref>{{Cite web | vauthors = Vossel H |date=2024-05-21 |title=Laws in Motion to Bring 'Right to Try' Psychedelics at End-of-Life |url=https://hospicenews.com/2024/05/21/laws-in-motion-to-bring-right-to-try-psychedelics-at-end-of-life/ |access-date=2025-02-13 |website=Hospice News |language=en-US}}</ref>